Publish time: 2021-12-14 00:00:00
28A-1101116
USP
The two chimera monoclonal antibodies identified here
were isolated from mono-GlcNAc decorated spike
protein immunized mice. The variable region of one
recognizes RBD region of Spike protein of SARS-CoV-2
and various variants, and constant region is from human,
and then possesses neutralizing activity against various
variants of SARS-CoV-2 pseudoviruses, including WH01
and delta variant. Another chimera monoclonal antibody
recognizes S2 region of Spike protein and variants of
SARS-CoV-2, and constant region is from human.
- High binding affinity against Spike protein
- The antibody can be chemically engineered to carryhomogenous complex-type glycan with fluoride modification toenhance antibody dependent cellularcytotoxicity (ADCC)
ability
- SARS-CoV-2 detection/diagnosis
- SARS-CoV-2 therapy
Kuo-I Lin, Chi-Huey Wong, Szu-Wen Wang, Yi-Hsuan Chang.
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Mono-GlcNAc decorated spike protein-elicited monoclonal antibodies in mice possess protective activity against various SARS-CoV-2 variants